Biotech Values

[NP1986]

I was one of the ones who voted that GILD didn't overpay for VRUS. I'm still not sure of whether they did overpay, but strategically I think it is the correct decision for GILD. They already have a good reach with hepatitis C treaters by virtue of the fact that they have been major players in HIV and hepatitis B. If they are able to replicate what they did with HIV in terms of market share, then I think future revenues from their hepatitis C portfolio justifies the price for VRUS.

I'm just kicking myself right now for not buying VRUS shares in the summer. But GILD is starting to look attractive to me - I probably should have pulled the trigger yesterday.